PhoreMost
PhoreMost is building a pipeline of novel drug discovery programs aimed at addressing a range of diseases, with a mission to accelerate, diversify and rationalize drug discovery.
Latest Content
Article
High-Throughput Effector Protein Remodeling for Molecular Glue Drug Discovery
Molecular glues hold strong therapeutic promise for approaches such as targeted protein degradation (TPD) and beyond, yet systematic identification remains challenging. But GlueSEEKER could help to overcome this problem.
Industry Insight
Molecular Glues Meet Precision Discovery To Advance Oncology Treatments
From theory to clinic, explore how molecular glue innovation is transforming targeted protein degradation for cancer and other diseases. Offering a new path to degrade targets once thought undruggable.
Product News
PhoreMost Achieves Second Milestone in Target Discovery Alliance With Boehringer Ingelheim
Milestone payment follows successful target identification and validation in separate project under same collaboration.
Industry Insight
Expanding the Druggable Space With Degradation-Based Therapies
We spoke with Dr. Christian Dillon to learn more about degradation-based therapies, the challenges associated with their discovery and how innovative solutions are helping to realize the potential of this promising class of therapeutics.
Product News
PhoreMost Enters Multi-Project Drug Target Discovery Collaboration With Roche
PhoreMost Ltd. today announced it has entered into a multi-project target discovery collaboration with Roche.
Industry Insight
A Platform That Could Help Identify and Target the “Undruggable”
We spoke to Neil Torbett, PhD, CEO of PhoreMost to learn more about “undruggable” targets and how the SITESEEKER® platform can identify these novel sites in the human proteome.
Advertisement
